Comparing Medpace (NASDAQ:MEDP) and Selectis Health (OTCMKTS:GBCS)

Selectis Health (OTCMKTS:GBCS) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Valuation and Earnings

This table compares Selectis Health and Medpace”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Selectis Health	$41.44 million	0.41	-$1.02 million	($0.34)	-16.18
Medpace	$2.53 billion	6.63	$451.12 million	$17.06	35.25

Medpace has higher revenue and earnings than Selectis Health. Selectis Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Selectis Health and Medpace’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Selectis Health	-2.45%	N/A	-3.03%
Medpace	17.67%	110.15%	24.84%

Institutional & Insider Ownership

78.0% of Medpace shares are held by institutional investors. 15.2% of Selectis Health shares are held by company insiders. Comparatively, 20.5% of Medpace shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Selectis Health has a beta of -1.07, meaning that its stock price is 207% less volatile than the S&P 500. Comparatively, Medpace has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Selectis Health and Medpace, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Selectis Health	0	0	0	0	0.00
Medpace	1	11	2	0	2.07

Medpace has a consensus price target of $560.92, suggesting a potential downside of 6.73%. Given Medpace’s stronger consensus rating and higher possible upside, analysts clearly believe Medpace is more favorable than Selectis Health.

Summary

Medpace beats Selectis Health on 14 of the 14 factors compared between the two stocks.

About Selectis Health

Selectis Health owns and/or operates healthcare facilities in Arkansas, Georgia, Ohio, and Oklahoma, providing a wide array of living services, speech, occupational, physical therapies, social services, and other rehabilitation and healthcare services. Selectis focuses on building strategic relationships with local communities in which its partnership can improve the quality of care for facility residents. With its focused growth strategy, Selectis intends to deepen its American Southcentral and Southeastern market presence to better serve the aging population along a full continuum of care.

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.